Vaccine Market - By Technology & Types, Trend Analysis By Various Classes - Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic Vaccines And By Indications - Infectious Diseases, Cancer, Allergy, Diabetes, Cardiovascular Disease With Market Landscape Analysis - Global Forecasts To 2022

Date: August 12, 2013
Pages: 195
Price:
US$ 4,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V1EF8A3C425EN
Leaflet:

Download PDF Leaflet

The vaccine market is an established segment and is widely accepted as an indispensable division of the healthcare industry. It is poised to grow rapidly by addressing the following: emerging infectious agents, various types of cancer, allergies, cardiovascular diseases, diabetes, smoke cessation, and neurodegenerative disorders. The global vaccine market is estimated at $32.05 billion in 2013 and is expected to reach $84.44 billion by 2022.

In general, the vaccine market is largely perceived negatively as a low-profit venture owing to the domination of top five companies, namely, Sanofi (France), Glaxo Smithkline (U.K.), Merck (U.S.), Pfizer (U.S.), and Novartis (Switzerland). Furthermore, a strong patent portfolio and the need for large investments towards vaccine development have limited the scope of entry for new companies.

The vaccine market is analyzed both in terms of qualitative (technological) and quantitative (revenue) perspectives. The technological analysis includes a discussion on different classes of vaccines, vaccine adjuvants, and commercially available products. The market revenue analysis includes market segmentation and the expected market position by 2022, with the projected growth rate.

The vaccine market is classified by technology class, types, end users, disease indication, and geography. The details on the emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are discussed. Furthermore, key research centers, with their critical areas of research in the vaccine space, have been provided.

An overview of regulations across various geographical regions has been covered. The complete value chain of the vaccine market is schematically represented and the significance of each stakeholder has been briefed.

Apart from the technological and market analysis, the investor climate has been assessed by tracking the complete investor network and collecting data on funds/grants and investments made towards vaccine development. Insights on current and future technological investment trends have also been discussed.

A large number of potential therapeutic and preventive vaccine candidates addressing various diseases which are in the pipeline are listed with their current status in clinical trials.
The adoption and developmental potential of the vaccine technology market has been discussed on a geographic basis, namely, North America, Europe, Asia, and the Rest of the World, by taking select countries that are poised to have a greater market value during the forecast period.

In brief, this research report provides:
  • A detailed description of the global technology developments and evolving trends in the vaccine field with key prominence on research innovations, collaborative efforts, and investments for vaccines.
  • A close view on the therapeutic vaccines for various diseases by providing details and status of current vaccines in the pipeline.
  • An impact analysis of the major drivers and restraints influencing the adoption and growth of the vaccine market during the period of 2013 to 2022.
  • Porters five forces analysis and GAP analysis.
  • The global market forecast for 2013 - 2022, including demand side analysis and strategic recommendations for technology/product developers.
  • Competitive landscape tracking industry activities such as mergers, acquisitions, partnerships, collaborations, and strategic agreements within the vaccine market. Intellectual property strength analysis based on the number of patents filed by the top five players within the vaccine market that gives an insight into prominent activities and global leaders of the industry.
Scope of the Report

This research report categorizes the global vaccine market into technology class, types, end users, disease indication, and geography. Each segment is further broken down by geography, with exhaustive revenue analysis for 2012 and 2013, as well as the forecast up to 2022.

Global Vaccine Market, by Technology Class
  • Live
  • Toxoid
  • Conjugate
  • Sub-Unit
  • Recombinant Vector Vaccines
  • DNA Vaccines
  • Synthetic Vaccines
  • Dentritic Vaccines
Global Vaccine Market, by Types
  • Preventive
  • Therapeutic
Global Vaccine Market, by End Users
  • Pediatric
  • Adult
Global Vaccine Market, by Disease Indication
  • Infectious Diseases
  • Cancer
  • Allergies
  • Others
Global Vaccine Market, by Geography
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)
1 INTRODUCTION

1.1 Key Take-Aways
1.2 Report Scope
1.3 Report Segmentation
1.4 Research Methodology
1.5 Key Data Points From Secondary and Primary Sources
1.6 Logical Assumptions in this Study Based on Reliable Sources

2 EXECUTIVE SUMMARY

3 TECHNOLOGY SNAPSHOT

3.1 Technology – Introduction
3.2 Technology – Evolution
3.3 Technology Segmentation
3.4 Technology Trends – by Class
  3.4.2 Adjuvants
3.5 Key Vaccine Products in the Market
3.6 Technology Roadmap

4 VACCINE RESEARCH PORTFOLIO

4.1 Global Research Portfolio – Research and Development Network
4.2 Emerging Approaches to Vaccine Developments
4.3 Key Research Centres

5 VALUE CHAIN ANALYSIS

5.1 Overview
5.2 Cold Chain Management
5.3 Key Stakeholders
5.4 Gap Analysis
5.5 Porters Five Force Analysis

6 MARKET LANDSCAPE

6.1 Global Vaccine Technologies Market, Global Forecasts (2013 – 2022)
  6.1.1 Global Vaccine Technologies Market, By Geography, 2012 – 2022
  6.1.2 Vaccine Technologies Market Segmentation
  6.1.3 Market Dynamics
    6.1.3.1 Drivers
    6.1.3.2 Restraints
    6.1.3.3 Opportunities, Threats and Challenges
6.2 Global Vaccine Technologies Market, By End-User, 2012-2022
  6.2.1 Global Vaccine Technologies Market Share, By End-User, 2012 – 2022
  6.2.2 Paedriatic Vaccine Market, By Geography
  6.2.3 Global Paedriatic Vaccine Market Share, By Geography
  6.2.4 Global Adult Vaccine Market, By Geography
  6.2.5 Global Adult Vaccine Market Share, By Geography
6.3 Global Vaccine Technologies Market, By Type, 2012-2022
  6.3.1 Global Vaccine Technologies Market Share, By Type, 2012-2022
  6.3.2 Global Preventive Vaccine Market, By Geography, 2012 – 2022
  6.3.3 Global Preventive Vaccine Market Share, By Geography, 2012-2022
  6.3.4 Global Therapeutic Vaccine Market, By Geography, 2012 – 2022
  6.3.5 Global Therapeutic Vaccine Market Share, By Geography, 2012 – 2022
6.4 Global Vaccine Technologies Market, By Class, 2012 – 2022
  6.4.1 Global Vaccine Technologies Market Share, By Class, 2012-2022
  6.4.2 Live/Attenuated Vaccine Market, By Geography
    6.4.2.1 Live/ Attenuated Vaccine Market Share, By Geography
  6.4.3 Toxoid Vaccine Market, By Geography
    6.4.3.1 Toxoid Vaccine Market Share, By Geography
  6.4.4 Conjugate Vaccine Market, By Geography
    6.4.4.1 Conjugate Vaccine Market Share, By Geography
  6.4.5 Sub-unit Vaccine Market, By Geography
  6.4.6 Recombinant Vector Vaccine Market, By Geography, 2012 – 2022
    6.4.6.1 Recombinant Vector Vaccine Market Share, By Geography, 2012 – 2022
  6.4.7 DNA Vaccine Market, By Geography, 2012 – 2022
  6.4.8 Synthetic Vaccine Market, By Geography, 2012 – 2022
    6.4.8.1 Synthetic Vaccine Market Share, By Geography, 2012 – 2022
  6.4.9 Dentritic Vaccine Market, By Geography, 2012 – 2022
    6.4.9.1 Dentritic Vaccine Market Share, By Geography, 2012 – 2022
6.5 Vaccine Market, By Disease Indication (2012 - 2022)
  6.5.1 Infectious Disease Vaccine Market, By Geography
  6.5.2 Cancer Vaccine Market, By Geography
  6.5.3 Allergy Vaccine Market, By Geography
  6.5.4 Others Vaccine Market, By Geography, 2012 – 2022
  6.5.5 Others Potential Market, By Geography, 2016 – 2022

7 TECHNOLOGY ADOPTION

7.1 Factors that Drive Adoption of Vaccine Technologies (Demand and Supply Side Analysis)
7.2 North America – U.S. & Canada
7.3 Europe – U.K, Germany, France, Italy
7.4 Asia – China, India
7.5 RoW – Australia & Africa

8 INVESTMENT ANALYSIS

8.1 Investor Network
8.2 Investment Funding Analysis
8.3 Top Funding Organizations

9 COMPETITIVE LANDSCAPE

9.1 Competitive Landscape Analysis – Overview
9.2 Key Acquisitions/Partnerships/Agreements/Collaborations (2012 – 2013)
9.3 Vaccine Candidates in Pipeline – Allergy
9.4 Vaccine Candidates in Pipeline – Cancer
9.5 Vaccine Candidates in Pipeline – Infectious Diseases
9.6 Vaccine Candidates in Pipeline – Others

10 REGULATORY LANDSCAPE

10.1 Regulatory Landscape – Overview
10.2 Regulations – Geographic
11 PATENT ANALYSIS
11,1 PATENT ANALYSIS – OVERVIEW
11,2 PATENT ANALYSIS BY COMPANY

12 ANALYST RECOMMENDATIONS

12.1 Introduction
12.2 Technology Management Strategies

13 COMPANY PROFILES

13.1 NOVARTIS AG
13.2 GLAXO SMITHKLINE PLC
13.3 MERCK & CO., INC.
13.4 SANOFI
13.5 PFIZER, INC.
13.6 ANTIGEN EXPRESS, INC.
13.7 ADURO BIOTECH
13.8 GENTICEL
13.9 BIONDVAX PHARMACEUTICALS LTD
13.10 IMMUNE TARGETING SYSTEMS (ITS)
13.11 PROKARIUM
13.12 IMMUNOBIOLOGY LTD
13.13 LIQUIDIA TECHNOLOGIES
13.14 ALPHAVAX
13.15 BAVARIAN NORDIC

14 APPENDIX

Inter-country Comparison of Mortality for Selected Cause of Death

LIST OF FIGURES

Fig -1 GLOBAL VACCINE MARKET, 2007 – 2012 ($BILLION)
Fig -2 GLOBAL VACCINE TECHNOLOGIES MARKET, 2012 – 2022 ($BILLION)
Fig -3 Porter’s Value Chain Analysis
Fig -4 GLOBAL VACCINE MARKET, 2007 – 2012 ($BILLION)
Fig -5 GLOBAL VACCINE TECHNOLOGIES MARKET, 2013 – 2022 ($BILLION)
Fig -6 VACCINE TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
Fig -7 VACCINE TECHNOLOGIES MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -8 GLOBAL VACCINE TECHNOLOGIES MARKET, BY END-USER, 2012 – 2022 ($BILLION)
Fig -9 GLOBAL VACCINE TECHNOLOGIES MARKET SHARE, BY END-USER, 2012 – 2022
Fig -10 PAEDRIATIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -11 PAEDRIATIC VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -12 ADULT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -13 ADULT VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -14 GLOBAL VACCINE TECHNOLOGIES MARKET, BY TYPE, 2012 – 2022
Fig -15 GLOBAL VACCINE TECHNOLOGIES MARKET SHARE, BY TYPE, 2012 – 2022
Fig -16 PREVENTIVE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -17 PREVENTIVE VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -18 THERAPEUTIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -19 THERAPEUTIC VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -20 GLOBAL VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY CLASS, 2012 – 2022 ($Billion)
Fig -21 GLOBAL VACCINE TECHNOLOGIES MARKET SHARE, BY CLASS, 2012 - 2022
Fig -22 LIVE/ATTENUATED VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -23 LIVE/ATTENUATED VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -24 TOXOID VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -25 TOXOID VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -26 CONJUGATE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -27 CONJUGATE VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -28 SUBUNIT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
Fig -29 SUB-UNIT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -30 RECOMBINANT VECTOR VACCINE MARKET, BY GEOGRAPHY, 2012-2022
Fig -31 RECOMBINANT VECTOR VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -32 DNA VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
Fig -33 DNA VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -34 SYNTHETIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -35 SYNTHETIC VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -36 DENTRITIC VACCINES, BY GEOGRAPHY, 2012 – 2022
Fig -37 DENTRITIC VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -38 GLOBAL VACCINE MARKET, BY DISEASE INDICATION, 2012 – 2022
Fig -39 GLOBAL VACCINE MARKET SHARE, BY DISEASE INDICATION, 2012 – 2022
Fig -40 INFECTIOUS DISEASE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -41 INFECTIOUS DISEASE VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -42 CANCER VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
Fig -43 CANCER VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -44 ALLERGY VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -45 ALLERGY VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022
Fig -46 OTHERS (CARDIOVASCULAR DISEASE, DIABETES, SMOKE CESSATION) POTENTIAL MARKET, BY GEOGRAPHY, 2016 – 2022 ($BILLION)
Fig -47 OTHERS (CARDIOVASCULAR DISEASE, DIABETES, SMOKE CESSATION) POTENTIAL MARKET, BY GEOGRAPHY, 2016 – 2022
Fig -48 GLOBAL VACCINE TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012 – 2022
Fig -49 VACCINE- INVESTOR NETWORK
Fig -50 GLOBAL VACCINE MARKET SHARE, BY KEY PLAYER, 2013
Fig -51 REGULATORY APPROVAL PROCESS
Fig -52 TOTAL PATENTS FILED BETWEEN 2008 – 2013
Fig -53 PATENT ANALYSIS BY COMPANIES (2008 – 2012)

The global vaccine technology market is anticipated to reach around $84 billion by 2022, growing at a CAGR of 11.36%. The vaccine market is divided by technology class (Live/Attenuated, Toxoid, Conjugate, Sub-Unit, Recombinant Vector, DNA, Synthetic, and Dentritic Vaccines), types (Preventive and Therapeutic), end users (Pediatric and Adult), disease indication (Infectious Diseases, Cancer, Allergies, and Others – Diabetes, Cardiovascular Diseases), and geography (North America, Europe, Asia, and Rest of the World). Furthermore, each technology class, type, end user, and disease indication segment is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned disease indication segments, infectious disease vaccines are the largest revenue segment; however, cancer vaccines will be the fastest-growing segment with the highest CAGR.

The potential growth of the market is attributed towards therapeutic vaccines, allergy vaccines, and emerging-disease vaccines. Improved understanding of immunology, new technological breakthroughs in the development of a new class of vaccines, namely, recombinant vector vaccines, DNA vaccines, and dendritic vaccines coupled with excellent distribution channels are propelling the growth of this market. Furthermore, a large population base in emerging economies and a high prevalence of diseases is driving the market, which is expected to remain consistent in the coming years. Largely popular as the biological preparation exclusively for the prevention of diseases, vaccines are now emerging as therapeutic agents for improving the immune system. This is adding a new dimension to the vaccine industry, opening doors for the treatment of various ailments, especially cancer, cardiovascular disease, diabetes, and smoke cessation. These opportunities have also paved the way for the entry of new companies and for the development of newer technology platforms. Furthermore, new emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are paving the way for the development of new effective vaccines capable of addressing current and emerging infectious diseases and cancers.

North America (42%) is a significant contributor, followed by Europe (36%), due to the highly structured healthcare reimbursement policies and the high purchasing power of costly vaccines. The new markets for vaccine are expected to grow at a vigorous pace in emerging economies such as China, India, and other regions in Asia-Pacific and untapped markets in Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.

The key players in this market are Novartis (Switzerland), Glaxo Smithkline (U.K.), Merck (U.S.), Sanofi (France), Pfizer (U.S.), Antigen Express, Inc. (U.S.), Aduro Biotech (U.S.), Genticel (France), Biondvax (Israel), Immune Targeting Systems (U.K.), Prokarium (U.K.), Immunobiology Ltd. (U.K.), Liquidia Technologies (U.S.), Alphavax (U.S.), and Bavarian Nordic (Denmark).

The material was prepared in August, 2013.

LIST OF TABLES

VACCINE TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
GLOBAL VACCINE TECHNOLOGIES MARKET, BY END-USER, 2012 – 2022 ($BILLION)
PAEDRIATIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
ADULT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
GLOBAL VACCINE TECHNOLOGIES MARKET, BY TYPE, 2012 – 2022 ($BILLION)
GLOBAL PREVENTIVE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ( $BILLION)
THERAPEUTIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
GLOBAL VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY CLASS, 2012 – 2022 ($BILLION)
GLOBAL LIVE VACCINE MARKET, BY GEOGRAPHY, 2012-2022 ($BILLION)
TOXOID VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
CONJUGATE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
SUBUNIT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
RECOMBINANT VECTOR VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
DNA VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
SYNTHETIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022
DENTRITIC VACCINE MARKET, BY GEOGRAPHY, 2017 – 2022 ($BILLION)
GLOBAL VACCINE MARKET, BY DISEASE INDICATION, 2012 – 2022 ($BILLION)
INFECTIOUS DISEASE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
CANCER VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
ALLERGY VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION)
OTHERS (CARDIOVASCULAR DISEASE, DIABETES, SMOKE CESSATION) POTENTIAL MARKET, BY GEOGRAPHY, 2016 – 2022 ($BILLION)
REVENUE OF TOP 5 COMPANIES

Ask Your Question

Vaccine Market - By Technology & Types, Trend Analysis By Various Classes - Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic Vaccines And By Indications - Infectious Diseases, Cancer, Allergy, Diabetes, Cardiovascular Disease With Market Landscape Analysis - Global Forecasts To 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: